SLNOSoleno Therapeutics, Inc.

$2B

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$41M

Net Income

-$39M

EPS (Diluted)

$-2.36

Cash Flow

Operating Cash Flow

-$25M

Free Cash Flow

-$25M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$181M

Total Liabilities

$23M

Stockholders' Equity

$158M

Cash & Equivalents

$170M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$41M	-$24M	-69.6%
Net Income	-$39M	-$24M	-62.0%

SLNO FY 2023 Earnings — Soleno Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena